Related pages Drug Information Summaries Approval Process for New Cancer Treatments Access to Investigational Drugs: Q & A

This page contains brief information about aldesleukin and a collection of links to more information from the National Cancer Institute (NCI), the Food and Drug Administration (FDA), and the National Library of Medicine (NLM).

US Brand Name(s):		Proleukin
FDA Approved:		Yes

Aldesleukin is approved by the Food and Drug Administration (FDA) to treat adults with renal cell carcinoma (RCC) or melanoma that has metastasized (spread to other parts of the body). It is used to treat patients who are otherwise in good health.

Aldesleukin is also called interleukin-2 (IL-2). It is being studied in the prevention and treatment of other conditions and types of cancer.

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

Biological Therapies for Cancer: Questions and Answers (06/13/2006) - Information about the use of this drug to treat cancer.

Biological Therapy (11/14/2004) - Information from NCI about this drug.

Alternative Vaccine Strategy Shows Promise in Prostate Cancer Patients (08/15/2008) - Information from the NCI Press Office about this drug.

NCI Researchers Confirm the Effectiveness of Immunotherapy Approach to Treating Melanoma (03/31/2005) - Information from the NCI Press Office about this drug.

Modifying Immune System Response to Cancer Chemotherapy Could Lead to New Treatment Approaches (10/31/2005) - Information from the NCI Press Office about this drug.

MedlinePlus Information on Aldesleukin - A lay language summary of important information about this drug that may include the following:

• warnings about this drug,
• what this drug is used for and how it is used,
• what you should tell your doctor before using this drug,
• what you should know about this drug before using it,
• other drugs that may interact with this drug, and
• possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This NLM patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Clinical Trials for Aldesleukin - Check for trials from NCI's PDQ Cancer Clinical Trials Registry now accepting patients.

Back to Top